Skip to main content
Erschienen in: Digestive Diseases and Sciences 12/2016

01.10.2016 | Original Article

A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients

verfasst von: David N. Assis, Hiroki Takahashi, Lin Leng, Mikio Zeniya, James L. Boyer, Richard Bucala

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The pathogenesis of autoimmune hepatitis (AIH) is incompletely understood. Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine implicated in the pathophysiology of multiple autoimmune diseases. We recently reported that MIF expression was increased in a US AIH cohort. MIF expression in non-Western AIH patients is unknown. A MIF-173 GC single nucleotide polymorphism in the MIF promoter (rs755622) is clinically associated with steroid resistance in several inflammatory disorders but has not been evaluated in AIH.

Aim

To compare MIF polymorphisms and their relationship to clinical parameters in AIH patients from the USA and Japan.

Methods

DNA and matched sera from AIH patients and healthy controls from Japan (N = 52) were compared to the US group. Serum concentrations of MIF and its circulating receptor CD74 were measured by ELISA. MIF-173 GC (rs755622) and MIF-794 CATT5–8 (rs5844572) polymorphisms were analyzed by standard methods. MIF genotypes were correlated with serum ALT and steroid requirements.

Results

Serum MIF was increased in Japanese AIH patients versus local controls, in agreement with the US AIH patients. Within both AIH groups, ALT was higher in CC/GC versus GG patients. Further, the steroid requirement was higher in AIH patients with GC/CC genotypes from both groups. In the Japanese patient group, the GC/CC genotype also was associated with acute symptomatic presentation.

Conclusions

The MIF-173 CC/GC genotypes may be associated with both higher ALT and maintenance steroid requirements in AIH patients from the USA and Japan. This polymorphism could be a marker of disease severity in AIH patients.
Literatur
1.
Zurück zum Zitat Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. Lancet. 2013;382:1433–1444.CrossRefPubMed Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. Lancet. 2013;382:1433–1444.CrossRefPubMed
2.
Zurück zum Zitat de Boer YS, van Gerven NM, Zwiers A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014;147:443–452.CrossRefPubMed de Boer YS, van Gerven NM, Zwiers A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014;147:443–452.CrossRefPubMed
3.
Zurück zum Zitat Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.CrossRefPubMed Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.CrossRefPubMed
4.
Zurück zum Zitat Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995;377:68–71.CrossRefPubMed Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995;377:68–71.CrossRefPubMed
5.
Zurück zum Zitat Calandra T, Bucala R. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol. 1997;17:77–88.CrossRefPubMed Calandra T, Bucala R. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol. 1997;17:77–88.CrossRefPubMed
6.
Zurück zum Zitat Bucala R. MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity. J Clin Immunol. 2013;33:S72–S78.CrossRefPubMed Bucala R. MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity. J Clin Immunol. 2013;33:S72–S78.CrossRefPubMed
7.
Zurück zum Zitat Sreih A, Ezzeddiine R, Leng L, et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum. 2011;63:3942–3951.CrossRefPubMedPubMedCentral Sreih A, Ezzeddiine R, Leng L, et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum. 2011;63:3942–3951.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Llamas-Covarrubias MA, Valle Y, Bucala R, et al. Macrophage migration inhibitor factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine. 2013;61:759–765.CrossRefPubMedPubMedCentral Llamas-Covarrubias MA, Valle Y, Bucala R, et al. Macrophage migration inhibitor factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine. 2013;61:759–765.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Wu SP, Leng L, Feng Z, et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum. 2006;54:3661–3669.CrossRefPubMed Wu SP, Leng L, Feng Z, et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum. 2006;54:3661–3669.CrossRefPubMed
10.
Zurück zum Zitat Murakami H, Akbar SM, Matsui H, Onji M. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest. 2001;31:337–343.CrossRefPubMed Murakami H, Akbar SM, Matsui H, Onji M. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest. 2001;31:337–343.CrossRefPubMed
11.
Zurück zum Zitat Nishihira J. Molecular function of macrophage migration inhibitory factor and a novel therapy for inflammatory bowel disease. Ann N Y Acad Sci. 2012;1271:53–57.CrossRefPubMedPubMedCentral Nishihira J. Molecular function of macrophage migration inhibitory factor and a novel therapy for inflammatory bowel disease. Ann N Y Acad Sci. 2012;1271:53–57.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Assis DN, Leng L, Du X, et al. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology. 2014;59:580–591.CrossRefPubMed Assis DN, Leng L, Du X, et al. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology. 2014;59:580–591.CrossRefPubMed
13.
Zurück zum Zitat Zhong XB, Leng L, Beitin A, et al. Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies. Nucleic Acids Res. 2005;33:e121.CrossRefPubMedPubMedCentral Zhong XB, Leng L, Beitin A, et al. Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies. Nucleic Acids Res. 2005;33:e121.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Barton A, Lamb R, Symmons D, et al. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun. 2003;4:487–491.CrossRefPubMed Barton A, Lamb R, Symmons D, et al. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun. 2003;4:487–491.CrossRefPubMed
15.
Zurück zum Zitat Berdeli A, Mir S, Ozkayin N, Serdaroglu E, Tabel Y, Cura A. Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome. Pediatr Nephrol. 2005;20:1566–1571.CrossRefPubMed Berdeli A, Mir S, Ozkayin N, Serdaroglu E, Tabel Y, Cura A. Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome. Pediatr Nephrol. 2005;20:1566–1571.CrossRefPubMed
16.
Zurück zum Zitat Shimizu T, Hizawa N, Honda A, et al. Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata. Genes Immun. 2005;6:285–289.CrossRefPubMed Shimizu T, Hizawa N, Honda A, et al. Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata. Genes Immun. 2005;6:285–289.CrossRefPubMed
17.
Zurück zum Zitat Zhang H, Ma L, Dong LQ, Shu C, Xu JL. Association of the macrophage migration inhibitory factor gene—173G/C polymorphism with inflammatory bowel disease: a meta-analysis of 4296 subjects. Gene. 2013;526:228–231.CrossRefPubMed Zhang H, Ma L, Dong LQ, Shu C, Xu JL. Association of the macrophage migration inhibitory factor gene—173G/C polymorphism with inflammatory bowel disease: a meta-analysis of 4296 subjects. Gene. 2013;526:228–231.CrossRefPubMed
18.
Zurück zum Zitat Nohara H, Okayama N, Inoue N, et al. Association of the -173G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol. 2004;39:242–246.CrossRefPubMed Nohara H, Okayama N, Inoue N, et al. Association of the -173G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol. 2004;39:242–246.CrossRefPubMed
19.
Zurück zum Zitat Vivarelli M, D’Urbano LE, Insalaco A, et al. Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids. Clin Exp Rheumatol. 2007;25:775–781.PubMed Vivarelli M, D’Urbano LE, Insalaco A, et al. Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids. Clin Exp Rheumatol. 2007;25:775–781.PubMed
20.
Zurück zum Zitat Vivarelli M, D’Urbano LE, Stringini G, et al. Association of the macrophage migration inhibitory factor -173*C allele with childhood nephrotic syndrome. Pedatr Nephrol. 2008;23:743–748.CrossRef Vivarelli M, D’Urbano LE, Stringini G, et al. Association of the macrophage migration inhibitory factor -173*C allele with childhood nephrotic syndrome. Pedatr Nephrol. 2008;23:743–748.CrossRef
21.
Zurück zum Zitat Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.CrossRefPubMed Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.CrossRefPubMed
22.
Zurück zum Zitat Cvetkovic I, Stosic-Grujicic S. Neutralization of macrophage migration inhibitory factor – novel approach for the treatment of immunoinflammatory disorders. Immunopharmacol. 2006;6:1527–1534. CrossRef Cvetkovic I, Stosic-Grujicic S. Neutralization of macrophage migration inhibitory factor – novel approach for the treatment of immunoinflammatory disorders. Immunopharmacol. 2006;6:1527–1534. CrossRef
23.
Zurück zum Zitat Bacher M, Metz CN, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A. 1996;93:7849–7854.CrossRefPubMedPubMedCentral Bacher M, Metz CN, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A. 1996;93:7849–7854.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Stosic-Gruficic S, Stojanovic I, Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. Autoimm Rev. 2009;8:244–249.CrossRef Stosic-Gruficic S, Stojanovic I, Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. Autoimm Rev. 2009;8:244–249.CrossRef
25.
Zurück zum Zitat Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol. 2004;31:268–273.PubMed Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol. 2004;31:268–273.PubMed
26.
Zurück zum Zitat Kim HR, Park MK, Cho ML, et al. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol. 2007;34:927–936.PubMed Kim HR, Park MK, Cho ML, et al. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol. 2007;34:927–936.PubMed
27.
Zurück zum Zitat Radstake TR, Sweep FC, Welsing P, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 2005;52:3020–3029.CrossRefPubMed Radstake TR, Sweep FC, Welsing P, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 2005;52:3020–3029.CrossRefPubMed
28.
Zurück zum Zitat van Gerven NM, Verwer BJ, Witte BI, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58:141–147.CrossRefPubMed van Gerven NM, Verwer BJ, Witte BI, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58:141–147.CrossRefPubMed
29.
Zurück zum Zitat Zeniya M, Takahashi H. Characteristics of autoimmune hepatitis in the Asia-Pacific Region: historical review. Hepatol Int. 2012;6:342–349.CrossRefPubMed Zeniya M, Takahashi H. Characteristics of autoimmune hepatitis in the Asia-Pacific Region: historical review. Hepatol Int. 2012;6:342–349.CrossRefPubMed
30.
Zurück zum Zitat Wang FF, Hugna XF, Shen N, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther. 2013;15:R65.CrossRefPubMedPubMedCentral Wang FF, Hugna XF, Shen N, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther. 2013;15:R65.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat van Gerven NM, de Boer YS, Zwiers A, et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun. 2015;16:247–252.CrossRefPubMed van Gerven NM, de Boer YS, Zwiers A, et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun. 2015;16:247–252.CrossRefPubMed
Metadaten
Titel
A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients
verfasst von
David N. Assis
Hiroki Takahashi
Lin Leng
Mikio Zeniya
James L. Boyer
Richard Bucala
Publikationsdatum
01.10.2016
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 12/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4322-z

Weitere Artikel der Ausgabe 12/2016

Digestive Diseases and Sciences 12/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.